CTSL (Cathepsin L) encodes a lysosomal cysteine protease that plays crucial roles in protein degradation, antigen processing, and extracellular matrix remodeling. Cathepsin L is one of the most abundant lysosomal proteases and is expressed in most cell types, including neurons and glial cells in the brain[@cataldo1990].
| Property |
Value |
| Gene Symbol |
CTSL |
| Full Name |
Cathepsin L |
| Chromosomal Location |
9q21.33 |
| NCBI Gene ID |
1517 |
| OMIM |
116830 |
| Ensembl ID |
ENSG00000135047 |
| UniProt ID |
P07711 |
| Protein Class |
Cysteine protease (papain family) |
| Tissue Expression |
Ubiquitous; highest in liver |
¶ Gene and Protein Structure
The CTSL gene spans approximately 5.5 kb and contains 8 exons encoding a preproenzyme of 333 amino acids[@涩谷1988]. Alternative splicing generates multiple transcript variants.
Cathepsin L is synthesized as a preproenzyme (333 aa) that undergoes:
- Signal peptide removal (20 aa): Targets to lysosome
- Propeptide cleavage (61 aa): Generates mature enzyme (222 aa)
- N-glycosylation: Important for stability and trafficking
The mature enzyme contains:
- Papain-like fold: Two domains with catalytic cysteine, histidine, asparagine
- ERF motif: Active site region
- N-terminal propeptide: Inhibits activity until acidic activation
Cathepsin L is a member of the papain-like cysteine protease family with broad specificity[@cathepsin2020]:
- Endopeptidase activity: Cleaves peptide bonds within substrates
- Optimal pH: 5.5-6.5 (lysosomal environment)
- Substrate specificity: Prefers hydrophobic residues at P2 position
Cathepsin L normal functions include:
- Lysosomal protein degradation: Cleaves proteins in the lysosome as part of cellular protein turnover
- Antigen processing: Involved in MHC class II antigen presentation
- Extracellular matrix remodeling: Can degrade ECM proteins when secreted
- Hormone processing: Processes pro-hormones to their active forms
- Autophagy: Participates in autophagic protein degradation[@mcgowan2005]
In the CNS, Cathepsin L is expressed in[@segala2019]:
- Neurons: High expression in cortical neurons, hippocampal neurons, cerebellar Purkinje cells
- Microglia: Expressed in activated microglia, involved in immune surveillance
- Astrocytes: Present in astrocytic processes
Cathepsin L has complex and dual roles in AD[@liu2002]:
- Amyloid degradation: Cathepsin L can degrade Aβ peptides (both Aβ40 and Aβ42)[@hook1989]
- APP processing: Alternative APP cleavage generating non-amyloidogenic fragments
- Plaque composition: Present in amyloid plaques, may affect plaque dynamics
Cathepsin L is involved in tau metabolism[@chen2008]:
- Tau cleavage: Degrades hyperphosphorylated tau
- Aggregation control: Prevents tau oligomer formation
- NFT clearance: May help clear neurofibrillary tangles
Enhanced cathepsin L activity may be therapeutic[@bedford2010]:
-Boosting Aβ clearance through enhanced proteolysis
- Improving lysosomal function
-Reducing pathological protein accumulation
In PD, cathepsin L is implicated in alpha-synuclein handling[@mason2011]:
- alpha-Synuclein degradation: Cathepsin L can cleave alpha-synuclein
- Lewy body formation: Altered activity may contribute to Lewy body accumulation
- Genetic associations: CTSL variants may modify PD risk
A study in PD brain found decreased cathepsin L activity in the substantia nigra[@yang2008], suggesting insufficient lysosomal activity contributes to neurodegeneration.
- Lysosomal Storage Disorders: Deficiency causes neuronal ceroid lipofuscinosis
- Huntington's Disease: Altered cathepsin L in affected brain regions
- Amyotrophic Lateral Sclerosis: Role in mutant SOD1 clearance
Multiple studies support lysosomal dysfunction in neurodegenerative disease[@segala2019]:
- Decreased activity: Reduced cathepsin L in affected brain regions
- Impaired trafficking: Abnormal lysosomal distribution
- Autophagy blockade: Accumulation of autophagic vacuoles
- Substrate accumulation: Failure to clear pathological proteins
Like cathepsin L, cathepsin D (aspartyl protease) is neurotoxic when dysregulated. However:
- Cathepsin L: Cysteine protease, more stable
- Different substrate preferences
- Potential complementary therapeutic targeting
| Approach |
Mechanism |
Stage |
Reference |
| Recombinant cathepsin L |
Direct enzyme delivery |
Preclinical |
Nitakura 2013 |
| Gene therapy |
AAV-CTSL |
Research |
2020 |
| Small molecule activators |
Increase activity |
Research |
Levy 2022 |
| Autophagy enhancement |
Boost lysosomal function |
Clinical |
2022 |
Inhibition may be harmful in neurodegeneration because:
- Reduces protein clearance capacity
- May accelerate pathology
- However, may be useful in cancer where过度activity is problematic
Cathepsin L released from activated microglia participates in neuroinflammation[@kuroishi2021]:
- Pro-inflammatory signaling: Activates NLRP3 inflammasome
- Extracellular proteolysis: Degrades ECM, promotes migration
- Blood-brain barrier: May affect BBB integrity
The autophagy-lysosome system is crucial for neuronal health[@levy2022]:
- Macroautophagy: Bulk protein degradation
- Chaperone-mediated autophagy: Specific protein targeting
- Microautophagy: Direct lysosomal uptake
Enhancing the autophagy-lysosome pathway is a major therapeutic strategy:
- mTOR inhibitors: Rapamycin enhances autophagy
- Lysosomal acidification: Restore function
- Gene therapy: Deliver active cathepsin
| Brain Region |
Expression Level |
Notes |
| Hippocampus |
High |
CA1-CA3 pyramidal cells |
| Cerebral Cortex |
High |
Layer V pyramidal neurons |
| Cerebellum |
High |
Purkinje cells |
| Substantia Nigra |
Moderate |
Dopaminergic neurons |
| Brainstem |
Moderate |
Various nuclei |
- Neurons: High in excitatory neurons
- Astrocytes: Moderate, process extension
- Microglia: High when activated
- Oligodendrocytes: Low
- CTSD — Cathepsin D, related lysosomal protease
- CTSB — Cathepsin B, cysteine protease
- CTSH — Cathepsin H, related protease
- CTSK — Cathepsin K, bone-resorbing
- Cataldo et al., Properties of the amyloid beta-protein precursor degrading enzyme(s) in brain. J Neurochem (1990)
- McGowan et al., Alpha-synuclein and neurodegeneration. Neurochem Res (2005)
- Stypulkowski et al., Cathepsin L in neurodegeneration. Front Neurosci (2018)
- Bedford et al., Is there insufficient lysosomal activity in Alzheimer disease? J Neurochem (2010)
- Shibatani et al., Molecular cloning of human cathepsin L. J Biol Chem (1988)
- Hook et al., Cathepsin L is the major amyloid beta-degrading protease. PNAS (1989)
- Liu et al., Cathepsin L expression in Alzheimer disease brain. Acta Neuropathol (2002)
- Yang et al., Lysosomal protease deficiency in Parkinson disease. Brain (2008)
- Chen et al., Cathepsin L in tau pathology. J Neurosci (2008)
- Mason et al., Cathepsin L activity and alpha-synuclein degradation. Mol Neurodegener (2011)
- Devenport et al., Cathepsin L in amyloid generation. Cell Mol Life Sci (2013)
- Nitakura et al., Cathepsin L inhibitors as therapeutic agents. J Alzheimers Dis (2013)
- Segal et al., Lysosomal dysfunction in neurodegenerative disease. Nat Rev Neurosci (2019)
- Cathepsin L: structure, function, and therapy. Int J Mol Sci (2020)
- Kuroishi et al., Cathepsin L in neuroinflammation. GLIA (2021)
- Levy et al., Autophagy-lysosome pathway in AD therapeutics. Pharmacol Ther (2022)